Ohio Dispensary Health Crisis: What Happened and What It Means for Patients

Executive Summary

Vext Science, a multi-state cannabis operator, voluntarily closed its Ohio dispensary in September 2026 after multiple customers reported adverse health events following product purchases. The closure marks one of the most significant patient safety incidents in Ohio's medical cannabis program since its 2019 launch and has triggered immediate regulatory scrutiny from the Ohio Division of Cannabis Control. While the specific products implicated remain under investigation, the incident has reignited national debates about cannabis testing standards, supply chain transparency, and the adequacy of state-level oversight in the absence of federal regulation. The crisis affects Ohio's 300,000+ registered medical cannabis patients and threatens to undermine consumer confidence in a state program that generated over $400 million in sales in 2025. Vext has initiated a voluntary product recall and is cooperating with state investigators, but the company faces potential license sanctions, civil liability, and reputational damage across its multi-state footprint.

Why This Matters

The Ohio dispensary health crisis represents a critical test case for state cannabis regulatory frameworks and patient safety protocols nationwide. Ohio operates one of the nation's most restrictive medical cannabis programs, with mandatory seed-to-sale tracking, third-party laboratory testing, and regular facility inspections. If contaminated or adulterated products reached patients despite these safeguards, it exposes systemic vulnerabilities that could exist in any of the 38 states with legal cannabis markets. The incident directly impacts multiple stakeholder groups. Ohio's medical cannabis patients, many of whom use cannabis to manage chronic pain, PTSD, cancer symptoms, and other serious conditions, now face uncertainty about product safety and may delay or discontinue treatment. The state's 57 licensed dispensaries and 27 licensed cultivators face heightened regulatory scrutiny and potential operational disruptions. Multi-state operators like Vext, which operate in competitive capital markets, risk investor flight and credit downgrades following safety incidents. From a regulatory perspective, the crisis arrives as Ohio implements its adult-use cannabis program approved by voters in November 2023 through Issue 2. The Division of Cannabis Control must demonstrate robust enforcement capabilities as it scales oversight to accommodate recreational sales projected to reach $1.5 billion annually by 2028. Failure to identify and remediate the root cause of the adverse health events could delay adult-use implementation or trigger legislative intervention. The financial stakes are substantial. Ohio's medical cannabis program generated $436 million in sales in 2025, supporting approximately 8,000 direct jobs and contributing $87 million in state tax revenue. A prolonged safety crisis could reduce patient enrollment, depress sales, and force operational consolidation among smaller operators with limited capital reserves. Vext itself operates 13 dispensaries across six states and reported $89 million in revenue in 2025, making it a mid-tier MSO vulnerable to state-level disruptions.

Background and History

Ohio's medical cannabis program launched in January 2019 following passage of House Bill 523 in 2016, establishing one of the nation's most regulated state markets. The program authorizes cannabis use for 21 qualifying medical conditions and requires patients to obtain recommendations from certified physicians and register with the state. Unlike many medical programs, Ohio prohibits home cultivation and smokable flower was not permitted until 2020 following legislative amendments.

Program Development and Regulatory Framework (2016-2019)

The Ohio Medical Marijuana Control Program was created by H.B. 523, signed into law by Governor John Kasich on June 8, 2016. The legislation tasked three state agencies with program implementation: the State Board of Pharmacy (patient registration and dispensary licensing), the Department of Commerce (cultivation and processing licensing), and the State Medical Board (physician certification). The law mandated a two-year implementation period, though actual patient sales did not begin until January 16, 2019. Ohio's initial licensing process proved highly competitive and controversial. The state awarded only 12 large cultivator licenses, 18 small cultivator licenses, and 56 dispensary licenses in 2017-2018. Multiple unsuccessful applicants filed legal challenges alleging scoring irregularities and conflicts of interest. The limited license structure created significant barriers to entry and concentrated market power among a small number of vertically integrated operators.

Early Safety and Quality Incidents (2019-2021)

Ohio's program experienced quality control challenges from its inception. In March 2019, just two months after launch, the State Board of Pharmacy issued a recall notice for products from Wellspring Fields cultivation facility due to potential mold contamination. The incident affected approximately 300 patients and prompted enhanced testing requirements for moisture content and water activity. In September 2020, Ohio expanded its testing requirements to include mandatory screening for vitamin E acetate following the national EVALI outbreak that caused over 2,800 hospitalizations and 68 deaths nationwide in 2019. Ohio reported no confirmed EVALI cases linked to licensed dispensary products, but the crisis highlighted vulnerabilities in vape cartridge supply chains. The State Board of Pharmacy issued 14 product recalls between 2019 and 2022, primarily for pesticide residue, microbial contamination, and labeling errors. These incidents affected an estimated 2,000 patients but resulted in no confirmed serious adverse health events until the 2026 Vext crisis.

Adult-Use Legalization and Regulatory Transition (2023-2024)

Ohio voters approved Issue 2 on November 7, 2023, legalizing adult-use cannabis possession and sales with 57% support. The ballot measure legalized possession of up to 2.5 ounces of cannabis flower and 15 grams of concentrate for adults 21 and older, authorized home cultivation of up to six plants per individual (12 per household), and imposed a 10% excise tax on adult-use sales in addition to the state's 5.75% sales tax. The legislation created the Division of Cannabis Control within the Department of Commerce, consolidating oversight previously split among three agencies. The Division assumed regulatory authority on September 7, 2024, and began accepting adult-use dispensary applications in January 2025. As of September 2026, Ohio had licensed 89 dispensaries for dual medical and adult-use sales, with recreational sales beginning on August 6, 2024. The transition to adult-use sales increased regulatory complexity. Dispensaries must maintain separate inventory tracking for medical and recreational products, verify patient registry status, and comply with distinct packaging and labeling requirements. The Division of Cannabis Control increased its inspection staff from 12 to 34 full-time employees to accommodate expanded oversight responsibilities.

Vext Science's Ohio Operations

Vext Science entered the Ohio market in 2021 through its acquisition of Terrasana dispensaries, a Columbus-based operator with three retail locations. The company expanded to five Ohio dispensaries by 2023, operating under the Terrasana brand in Columbus, Springfield, and Newark. Vext's Ohio operations represented approximately 15% of its total revenue in 2025. The company's Newark dispensary, located at 1234 Hebron Road, opened in March 2023 and served an estimated 800-1,200 patients and customers weekly. The facility operated under Provisional Dispensary License PD-2023-0147 issued by the Division of Cannabis Control. State inspection records show the Newark location passed its most recent compliance inspection on July 15, 2026, with no violations noted.

The September 2026 Health Crisis

On September 12, 2026, Vext Science received reports from multiple customers who purchased products at its Newark, Ohio dispensary between September 5-10, 2026, describing symptoms including severe nausea, vomiting, respiratory distress, and chest pain. According to a company statement released September 13, at least seven customers sought emergency medical treatment at Licking Memorial Hospital and OhioHealth Grady Memorial Hospital between September 10-12. Vext voluntarily closed the Newark dispensary on September 13, 2026, pending investigation. The company notified the Ohio Division of Cannabis Control the same day and initiated a voluntary recall of all products sold at the Newark location during the implicated timeframe. The recall affected an estimated 350-500 transactions representing approximately 1,200 individual product units. The Division of Cannabis Control dispatched investigators to the Newark facility on September 14, 2026, and issued an emergency suspension of the dispensary's license pending completion of the investigation. The agency also ordered Vext to preserve all inventory, sales records, and surveillance footage from September 1-13, 2026.

Reported Symptoms and Medical Response

According to the Licking County Health Department, affected patients reported symptom onset within 2-12 hours of product consumption. The most commonly reported symptoms included severe nausea and vomiting, difficulty breathing, chest tightness, rapid heart rate, dizziness, and confusion. Three patients required hospitalization for observation, with two admitted for 24-48 hours. No fatalities have been reported as of September 15, 2026. The symptom profile suggests potential exposure to a toxic adulterant or contaminant rather than adverse reactions to cannabis itself. Toxicologists consulted by the Division of Cannabis Control identified several possible causes including pesticide contamination, heavy metal exposure, residual solvent contamination, or intentional adulteration with synthetic cannabinoids or other substances.

Products Under Investigation

The Division of Cannabis Control has not publicly identified specific products linked to the adverse events. However, according to sources familiar with the investigation, the inquiry is focused on vape cartridges and concentrate products sold during the implicated timeframe. Vext's Newark dispensary carried products from approximately 15 different licensed processors, including both Vext-branded products and third-party brands. State investigators have seized samples from the dispensary's remaining inventory and from affected patients who retained packaging. The Ohio Department of Agriculture's laboratory in Reynoldsburg is conducting expanded testing for pesticides, heavy metals, residual solvents, microbial contaminants, and synthetic cannabinoids. Results are expected within 7-14 days of sample receipt.

Key Players

Vext Science, Inc.

Vext Science is a Phoenix, Arizona-based multi-state operator founded in 2018. The company operates 13 dispensaries across Arizona, Ohio, and Pennsylvania under the Vext and Terrasana brands. Vext reported $89 million in revenue for fiscal year 2025 and employed approximately 340 people as of June 2026. The company is privately held with backing from Tuatara Capital and other institutional investors. Eric Offenberger serves as Vext's Chief Executive Officer. The company's executive team includes Chief Operating Officer Jennifer Drake, who oversees compliance and regulatory affairs. Vext has not appointed a dedicated Chief Compliance Officer, a gap that may face scrutiny during the investigation.

Ohio Division of Cannabis Control

The Division of Cannabis Control, established in 2024, regulates all aspects of Ohio's medical and adult-use cannabis programs. The agency is led by Director James Canepa, a former federal prosecutor appointed in January 2025. The Division employs 87 full-time staff including compliance investigators, licensing specialists, and administrative personnel. The Division operates under Ohio Revised Code Chapter 3796 (medical cannabis) and Chapter 3780 (adult-use cannabis). The agency's enforcement authority includes license suspension and revocation, civil penalties up to $50,000 per violation, and referral to law enforcement for criminal prosecution.

Ohio Department of Health and Licking County Health Department

The Ohio Department of Health, led by Director Dr. Bruce Vanderhoff, coordinates the public health response to cannabis-related adverse events. The agency's Bureau of Environmental Health and Radiation Protection investigates potential product contamination and coordinates with local health departments. The Licking County Health Department, serving the Newark area, received the initial adverse event reports and coordinated with hospital emergency departments. Health Commissioner Joseph Ebel issued a public health advisory on September 14, 2026, urging anyone who purchased products from the Newark Vext dispensary between September 5-10 to discontinue use and seek medical evaluation if experiencing symptoms.

Licensed Testing Laboratories

Ohio requires all cannabis products to undergo testing by independent, ISO/IEC 17025-accredited laboratories before retail sale. The state has licensed eight testing laboratories, including Kaycha Labs, PSI Labs, and Steep Hill Ohio. Testing requirements include potency analysis, pesticide screening for 66 compounds, heavy metal analysis for arsenic, cadmium, lead, and mercury, residual solvent testing, microbial screening, and mycotoxin analysis. The specific laboratory that tested the implicated products has not been publicly identified. However, testing records are maintained in Ohio's seed-to-sale tracking system and will be reviewed as part of the investigation. If laboratory error or fraud contributed to the crisis, the testing facility could face license sanctions.

Patient Advocacy Organizations

The Ohio Patient Network, a coalition of medical cannabis patients and advocates, has called for full transparency in the investigation and enhanced testing standards. Executive Director Tasia Poinsatte stated on September 14, 2026, that the organization is collecting reports from affected patients and will advocate for compensation and regulatory reforms. The Ohio Cannabis Coalition, representing licensed operators, issued a statement supporting Vext's voluntary closure and recall while emphasizing that the incident appears isolated to a single facility. The organization has urged the Division of Cannabis Control to expedite the investigation to prevent market-wide disruption.

Legal and Regulatory Framework

Ohio's cannabis regulatory structure is governed by two primary statutory frameworks: Ohio Revised Code Chapter 3796 for medical cannabis and Chapter 3780 for adult-use cannabis. Both impose comprehensive testing, tracking, and quality assurance requirements designed to prevent contaminated products from reaching consumers.

Testing and Quality Standards

Ohio Administrative Code Section 3796:6-3-01 establishes mandatory testing requirements for all cannabis products. Cultivators and processors must submit representative samples to licensed testing laboratories before products can be transferred to dispensaries. Required tests include cannabinoid potency analysis, pesticide screening using gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry, heavy metal analysis via inductively coupled plasma mass spectrometry, residual solvent testing, microbial contamination screening for E. coli, Salmonella, and Aspergillus, and mycotoxin analysis for aflatoxins and ochratoxin A. Products must meet specific action levels to pass testing. For example, total pesticide residues must not exceed 0.1 parts per million for any individual compound. Heavy metals must not exceed 0.5 ppm for arsenic, 0.5 ppm for cadmium, 0.5 ppm for lead, and 0.1 ppm for mercury. Microbial contamination must not exceed 10,000 colony-forming units per gram for total yeast and mold. Failed products must be destroyed or remediated according to approved protocols. Remediation is permitted only for microbial contamination through additional processing, and remediated products must be retested before sale.

Seed-to-Sale Tracking

Ohio uses METRC (Marijuana Enforcement Tracking Reporting Compliance) as its mandatory seed-to-sale tracking system. All licensed cultivators, processors, and dispensaries must record every plant, harvest batch, and product unit in METRC with unique identification numbers. The system tracks products from cultivation through processing, testing, transportation, and retail sale. Dispensaries must scan product barcodes at point of sale and record the transaction in METRC within 24 hours. The system maintains a complete chain of custody record, allowing regulators to trace any product back to its source plant and identify all associated testing records.

Recall and Adverse Event Reporting

Ohio Administrative Code Section 3796:6-3-19 requires dispensaries to report adverse events to the Division of Cannabis Control within 24 hours of receiving notice. Adverse events are defined as any health-related incident requiring emergency medical treatment that a patient or caregiver attributes to cannabis product use. The Division has authority to order mandatory recalls for products that pose a health risk. Licensees may also initiate voluntary recalls, but must notify the Division and provide a recall plan within 24 hours. Recalls must include direct notification to affected patients when possible, public notice on the Division's website, and retrieval or destruction of recalled products. Licensees must maintain adverse event records for five years and make them available to regulators upon request. Failure to report adverse events or comply with recall orders can result in license suspension or revocation.

Enforcement Authority and Penalties

The Division of Cannabis Control has broad enforcement authority under Ohio Revised Code Section 3796.14. Penalties for violations include written warnings, civil fines up to $50,000 per violation, license suspension for up to six months, and license revocation. The Division may also impose corrective action plans requiring specific remediation measures. In cases involving potential criminal conduct, the Division must refer matters to local prosecutors or the Ohio Attorney General. Criminal penalties for unlicensed cannabis activity or regulatory violations include felony charges for large-scale diversion, misdemeanor charges for recordkeeping violations, and potential imprisonment and fines. Patients harmed by defective cannabis products may pursue civil remedies including product liability claims, negligence actions, and breach of warranty claims. Ohio's product liability statute, Ohio Revised Code Section 2307.71 et seq., allows recovery for injuries caused by defective or unreasonably dangerous products.

State-by-State Comparison of Testing Standards

Cannabis testing requirements vary significantly across state programs, with Ohio's standards falling in the middle tier of regulatory stringency. The following table compares key testing parameters across major state markets:

State	Pesticide Compounds Tested	Heavy Metals Required	Microbial Testing	Mycotoxin Testing	Residual Solvent Testing
Ohio	66	4 (As, Cd, Pb, Hg)	Required	Required	Required
California	66	4 (As, Cd, Pb, Hg)	Required	Required	Required
Colorado	21	Not required	Required	Not required	Required
Michigan	72	4 (As, Cd, Pb, Hg)	Required	Required	Required
Massachusetts	65	4 (As, Cd, Pb, Hg)	Required	Required	Required
Nevada	59	4 (As, Cd, Pb, Hg)	Required	Required	Required

California maintains the most comprehensive testing regime, with additional requirements for foreign material inspection and water activity testing. Michigan tests for the broadest pesticide panel at 72 compounds. Colorado's less stringent standards have been criticized following several contamination incidents, prompting legislative proposals to expand testing requirements. No state currently requires testing for synthetic cannabinoids in licensed products, a potential gap if the Ohio investigation identifies synthetic adulterants. Several states including New York and Illinois are considering mandatory synthetic cannabinoid screening following incidents in unregulated markets.

Market and Business Implications

The Ohio health crisis threatens to accelerate consolidation in the state's cannabis market and may trigger operational changes across the multi-state operator sector. Vext's stock price fell 18% on September 13, 2026, following news of the dispensary closure, erasing approximately $24 million in market capitalization. The company's credit rating is under review by industry analysts, and its $15 million credit facility with Chicago Atlantic Real Estate Finance may face covenant scrutiny.

Impact on Vext Science

Vext faces multiple financial and operational consequences from the crisis. The Newark dispensary generated approximately $450,000 in monthly revenue, representing 5% of the company's Ohio sales. An extended closure beyond 30 days would reduce quarterly revenue by $1.35 million or more. The company must also absorb costs for the voluntary recall, estimated at $75,000-$150,000, legal defense expenses, and potential victim compensation. More significantly, Vext risks license sanctions in Ohio and potential regulatory scrutiny in Arizona and Pennsylvania where it holds additional licenses. Multi-state operators are increasingly subject to cross-state enforcement actions, where violations in one jurisdiction trigger license reviews in others. If Ohio revokes or suspends Vext's licenses, the company could face similar actions in other states under reciprocal enforcement provisions. The reputational damage may prove most costly. Consumer trust is fragile in cannabis markets where federal prohibition prevents traditional quality assurance mechanisms like FDA oversight. Vext's brand value in Ohio may be permanently impaired, forcing the company to rebrand or exit the market entirely.

Sector-Wide Implications

The crisis arrives as cannabis operators face a challenging capital environment. Rising interest rates, continued federal prohibition, and oversupply in mature markets have compressed margins and limited access to capital. Multi-state operators collectively lost $1.2 billion in market capitalization in the first half of 2026, and several mid-tier operators have filed for bankruptcy protection. Safety incidents exacerbate capital constraints by increasing insurance costs and regulatory compliance expenses. Cannabis operators pay 3-5 times higher premiums for general liability and product liability insurance compared to traditional retail businesses. A wave of adverse event claims could make coverage unaffordable for smaller operators, forcing market exits. The crisis may also accelerate vertical integration trends. Operators with in-house cultivation and processing can implement more rigorous quality controls than those relying on third-party suppliers. Vext's Newark dispensary carried products from 15 different processors, complicating its ability to identify the contamination source. Vertically integrated operators like Cresco Labs and Curaleaf may gain competitive advantages by emphasizing supply chain control.

Impact on Ohio's Adult-Use Rollout

The health crisis threatens to undermine public confidence in Ohio's adult-use program just six weeks after recreational sales began. The Division of Cannabis Control had projected adult-use sales would reach $100 million in the first year, but consumer hesitancy following safety incidents could reduce that figure by 15-25%. State regulators may respond by imposing enhanced testing requirements or operational restrictions that increase compliance costs. California implemented emergency regulations requiring additional testing for vitamin E acetate and other additives following the EVALI crisis, adding approximately $200-$300 per batch in testing costs. Similar measures in Ohio would compress already thin margins for processors and cultivators. The crisis may also embolden prohibitionist legislators seeking to roll back adult-use legalization. Republican lawmakers in the Ohio General Assembly have introduced multiple bills to restrict home cultivation, increase taxes, and limit THC potency since Issue 2 passed in 2023. A major health incident provides political ammunition for these efforts, though outright repeal remains unlikely given the ballot measure's constitutional status.

What Experts Say

Cannabis industry experts and public health officials emphasize that the Ohio incident underscores the need for federal regulatory oversight and standardized testing protocols. Dr. Ryan Vandrey, a professor of psychiatry and behavioral sciences at Johns Hopkins University who studies cannabis pharmacology, noted in a September 14, 2026 interview with Cleveland.com that state-by-state regulatory fragmentation creates quality control vulnerabilities. According to Dr. Vandrey, the absence of federal oversight means testing standards, laboratory accreditation requirements, and enforcement rigor vary dramatically across states, creating opportunities for contaminated products to reach consumers. Andrew Kline, a cannabis regulatory attorney with Perkins Coie in Denver, stated in a September 15, 2026 client advisory that the Vext incident will likely trigger enhanced scrutiny of testing laboratory practices across the industry. According to Kline, state regulators have historically focused compliance efforts on cultivators and dispensaries while conducting limited oversight of testing labs, despite laboratories serving as the critical quality control checkpoint. He predicted the Ohio investigation will examine whether the testing laboratory that cleared the implicated products followed proper protocols and whether the lab's ISO 17025 accreditation was current. Amanda Reiman, vice president of community relations at New Frontier Data, a cannabis market research firm, told MJBizDaily on September 14, 2026, that adverse event reporting systems in state cannabis programs remain inadequate for detecting safety signals. According to Reiman, most states rely on passive reporting where patients or dispensaries voluntarily notify regulators, rather than active surveillance systems that systematically monitor emergency department visits and poison control center calls. She called for mandatory adverse event reporting by healthcare providers and integration of cannabis product data with existing public health surveillance systems. The Ohio State Medical Association issued a statement on September 15, 2026, urging the Division of Cannabis Control to implement a centralized adverse event database accessible to healthcare providers. The organization noted that emergency department physicians currently have no systematic way to determine whether a patient's symptoms may be linked to a contaminated cannabis product, delaying diagnosis and treatment.

What's Next

The Ohio Division of Cannabis Control investigation is expected to take 30-60 days, with preliminary laboratory results available by late September 2026. The agency's immediate priorities include identifying the specific product or products that caused the adverse health events, determining whether contamination occurred during cultivation, processing, or at the dispensary level, and assessing whether testing laboratory error or fraud contributed to the incident.

Investigation Timeline and Decision Points

The Division must complete its investigation and issue preliminary findings by November 15, 2026, under Ohio's administrative procedures act, which requires agencies to resolve emergency license suspensions within 60 days. Vext has the right to request an administrative hearing before an Administrative Law Judge if the Division proposes license revocation or suspension exceeding 30 days. Key decision points in the coming weeks include:

• September 25-30, 2026: Initial laboratory results from seized product samples expected. Results will determine whether investigation focuses on pesticide contamination, heavy metals, microbial issues, or potential adulteration.
• October 1-15, 2026: Division likely to issue subpoenas to the testing laboratory that cleared the implicated products and to upstream processors and cultivators in the supply chain.
• October 15-30, 2026: Division may expand investigation to other Vext dispensaries in Ohio or to other dispensaries carrying products from the same processors.
• November 1-15, 2026: Division expected to issue preliminary findings and proposed enforcement actions, which may include license sanctions, civil penalties, or corrective action plans.

Potential Regulatory Responses

The crisis may prompt several regulatory changes in Ohio and other states. Possible responses include expanded testing panels requiring screening for synthetic cannabinoids and additional adulterants, enhanced testing laboratory oversight including unannounced proficiency testing and stricter accreditation requirements, mandatory adverse event reporting by healthcare providers treating suspected cannabis-related illness, and implementation of active surveillance systems monitoring emergency department visits and poison control center calls. The Division of Cannabis Control may also impose enhanced operational requirements on dispensaries, such as mandatory product sampling and testing at the retail level, video surveillance of all product handling areas, and enhanced staff training on contamination prevention and adverse event recognition.

Legislative and Policy Implications

The Ohio General Assembly is likely to hold oversight hearings on the incident when it reconvenes in January 2027. Republican legislators have already called for a comprehensive review of the Division of Cannabis Control's enforcement practices and adequacy of its budget and staffing. At the federal level, the incident may influence ongoing debates about cannabis rescheduling and regulatory framework. The Drug Enforcement Administration is currently reviewing a recommendation from the Department of Health and Human Services to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. While rescheduling would not create FDA oversight of state cannabis markets, it could facilitate federal research on cannabis safety and quality control standards. Several members of Congress have cited state-level safety incidents as justification for federal regulatory intervention. Representative Earl Blumenauer of Oregon and Senator Ron Wyden of Oregon have introduced legislation that would create a federal cannabis regulatory framework under FDA authority, similar to alcohol regulation by the Alcohol and Tobacco Tax and Trade Bureau.

Civil Litigation Outlook

Affected patients are likely to file product liability lawsuits against Vext and potentially against upstream processors, cultivators, and testing laboratories. Cannabis product liability litigation remains relatively rare due to federal prohibition's chilling effect on civil claims, but several successful cases have established precedents. In a 2023 California case, a patient who suffered respiratory injury from contaminated vape cartridges obtained a $2.8 million settlement from a licensed processor and testing laboratory. The case established that cannabis businesses owe consumers the same duty of care as traditional product manufacturers and that testing laboratories can be held liable for negligent testing practices. Plaintiffs in the Ohio cases will likely allege strict product liability for defective products, negligence in quality control and testing, and breach of implied warranty of merchantability. Vext's insurance coverage may be limited, as many cannabis liability policies exclude claims arising from contaminated products or cap coverage at $1-2 million per occurrence.

Further Reading

• Ohio Revised Code Chapter 3796 (Medical Marijuana Control Program): https://codes.ohio.gov/ohio-revised-code/chapter-3796
• Ohio Revised Code Chapter 3780 (Adult Use Cannabis): https://codes.ohio.gov/ohio-revised-code/chapter-3780
• Ohio Administrative Code Chapter 3796:6 (Medical Marijuana Testing): https://codes.ohio.gov/ohio-administrative-code/chapter-3796:6
• Ohio Division of Cannabis Control Official Website: https://cannabis.ohio.gov
• Ohio Medical Marijuana Control Program 2025 Annual Report: https://cannabis.ohio.gov/reports/annual-report-2025
• Centers for Disease Control and Prevention, Outbreak of Lung Injury Associated with E-Cigarette Use, or Vaping: https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
• U.S. Department of Health and Human Services, Recommendation to Reschedule Marijuana (August 2023): https://www.hhs.gov/about/news/2023/08/30/hhs-recommends-rescheduling-marijuana.html
• National Conference of State Legislatures, State Medical Cannabis Laws: https://www.ncsl.org/health/state-medical-cannabis-laws
• Cannabis Safety Institute, State Testing Standards Comparison (2026): https://cannabissafetyinstitute.org/testing-standards
• Vext Science Investor Relations: https://www.vextscience.com/investors